Figure 5.

SIRT1 knockdown in CeA increases emotional pain vulnerability. A, Staining images of EGFP in CeA after CeA infusion of AAV-EGFP (control) or AAV-Cre under control of CaMKIIα promoter in low- and high-magnification images. B, Western blots (top) and group data (bottom) of SIRT1 and β-actin proteins 15 d after the intra-CeA infusions in WT type (SIRT1^w/w) and SIRT1-floxed (SIRT1^fl/fl) mice (n = 6 each group). C, Locomotor traces (top) and central time (bottom) in an open field test 15 d after intra-CeA infusion of AAV-Cre in SIRT1^w/w mice (n = 10) and in SIRT1^fl/fl mice (n = 7), and AAV-EGFP in SIRT1^f/f mice (n = 9). D, Immobility time in a forced swim test 15 d after similar CeA infusions of AAV-Cre in SIRT1^w/w mice (n = 10) and in SIRT1^fl/fl mice (n = 7), and AAV-EGFP in SIRT1^fl/fl mice (n = 9). E, F, Distance traveled (E) and travel velocity (F) in an open field test in the same three groups as in C. G, H, Percentage of depression-vulnerable rats (G) and anxiety-vulnerable rats (H) after similar intra-CeA infusions of the AAV vectors in the three groups of mice. I, Thresholds of mechanical pain in the three groups of mice (SIRT1^w/w+AAV-Cre, n = 10; SIRT1^fl/fl+AAV-Cre, n = 7; SIRT1^fl/fl+AAV-EGFP, n = 9). *p < 0.05 (SIRT1^fl/fl+AAV-Cre vs SIRT1^w/w+AAV-Cre); #p < 0.05 (SIRT1^fl/fl+AAV-Cre vs SIRT1^fl/fl+AAV-EGFP). **p < 0.01.